Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma

Table 4 Univariate analysis for recurrence-free and overall survivals in 85 patients who met the criteria

Factor	Covariate (n)	Reference (n)	Recurrence-free survival			Overall survival
			HR	95% CI	P	HR	95% CI	P
Gender	Female (23)	Male (62)	0.81	0.44-1.48	0.48	0.91	0.43-1.94	0.81
Child-Pugh score	B (14)	A (71)	0.83	0.43-1.61	0.58	1.06	0.46-2.43	0.89
Total bilirubin (mg/dL)	≥ 1 (43)	< 1 (42)	1.37	0.82-2.30	0.23	1.77	0.83-3.79	0.14
Albumin (mg/dL)	≤ 3.5 (39)	> 3.5 (46)	0.92	0.55-1.52	0.74	0.56	0.28-1.09	0.09
Prothrombin time (%)	≤ 80 (35)	> 80 (50)	1.25	0.75-2.08	0.40	0.82	0.42-1.61	0.56
Platelet (× 104/mm3)	< 10 (35)	≥ 10 (50)	1.05	0.63-1.76	0.84	0.98	0.50-1.92	0.95
ICG R15	≥ 15% (59)	< 15% (26)	1.37	0.79-2.38	0.27	1.51	0.70-3.26	0.29
Hepatitis C virus	Positive (68)	Negative (17)	1.42	0.75-2.70	0.28	1.46	0.60-3.52	0.40
Hepatitis B virus	Positive (8)	Negative (76)	0.63	0.25-1.57	0.32	0.56	0.13-2.34	0.43
Number of tumor	Multiple (8)	Single (77)	1.12	0.48-2.61	0.79	1.29	0.50-3.36	0.60
Size of tumor (cm)	> 3 (33)	≤ 3 (52)	1.08	0.64-1.81	0.78	1.27	0.63-2.56	0.50
Histology	Poor1 (10)	Well-mod2 (68)	1.32	0.56-3.11	0.53	3.03	0.89-10.29	0.08
Vascular invasion	Present (8)	Absent (75)	0.96	0.38-2.06	0.77	0.88	0.31-2.54	0.82
Stage by LCSGJ3	III + IV (9)	I+II (76)	1.41	0.64-3.12	0.39	1.80	0.74-4.35	0.20
AFP (ng/mL)	≥ 20 (52)	< 20 (33)	1.47	0.87-2.49	0.15	1.50	0.75-3.02	0.25
	≥ 100 (28)	< 100 (57)	0.77	0.42-1.39	0.39	0.80	0.36-1.75	0.57
	≥ 200 (16)	< 200 (69)	0.53	0.25-1.13	0.10	0.50	0.18-1.42	0.20
	≥ 400 (11)	< 400 (74)	0.57	0.23-1.43	0.23	0.53	0.13-2.21	0.38
DCP (mAU/mL )	≥ 40 (45)	< 40 (40)	1.73	1.03-2.92	0.04	1.46	0.75-2.82	0.27
	≥ 100 (26)	<100 (59)	1.67	0.96-2.91	0.07	1.71	0.83-3.50	0.14
	≥ 200 (16)	< 200 (69)	1.69	0.84-3.40	0.14	5.81	2.56-13.16	< 0.0001
	≥ 400 (11)	< 400 (74)	2.41	1.12-5.18	0.02	5.71	2.38-13.70	< 0.0001

n: Number of patients; HR: Hazard ratio; CI: Confidence interval.

¹Poorly differentiated;

²Well or moderately differentiated hepatocellular carcinoma;

³LCSGJ: Liver Cancer Study Group of Japan.